Table 2 Change in lipids at baseline before randomization and after 24 weeksa within each treatment arm: (A) triple therapy, (B) TNFi; (C) comparison of changes in routine lipids between the two treatment arms
A. Triple therapy, n=61 | ||||
|---|---|---|---|---|
Lipids (mg/dL) | Baseline | 24 weeks | Δ | p-valueb |
Total cholesterol | 215.3 (38.8) | 213.8 (38.2) | -1.5 (34.4) | 0.73 |
LDL-C | 112.4 (28.3) | 112.3 (28.3) | -0.1 (25.0) | 0.98 |
HDL-C | 55.9 (18.2) | 59.0 (17.8) | 3.1 (10.7) | 0.03 |
Triglycerides | 119.1 (48.4) | 108.5 (39.4) | -10.6 (40.9) | 0.048 |
TC/HDL-C | 3.9 (1.1) | 3.6 (1.0) | -0.3 (0.7) | 0.01 |
B. TNFi + MTX, n=61 | ||||
|---|---|---|---|---|
Lipids (mg/dL) | Baseline | 24 weeks | Δ | p-value |
Total cholesterol | 204.6 (39.8) | 214.7 (39.7) | 11.0 (26.1) | 0.002 |
LDL-C | 108.0 (27.7) | 113.8 (28.6) | 5.8 (18.9) | 0.02 |
HDL-C | 55.0 (13.5) | 57.9 (15.4) | 2.9 (10.1) | 0.03 |
Triglycerides | 106.5 (44.4) | 114.7 (49.9) | 8.2 (33.8) | 0.07 |
TC/HDL-C | 3.9 (1.3) | 3.9 (1.3) | 0 (0.6) | 0.86 |
C. Comparison of changes in lipids in between the treatment arms (TNFi vs. triple therapy) | |||
|---|---|---|---|
Lipids (mg/dL) | Betac | 95% CI | p-value |
Total cholesterol | 9.40 | -0.91, 19.70 | 0.07 |
LDL-C | 4.65 | -2.92, 12.23 | 0.23 |
HDL-C | -0.10 | -3.78, 3.57 | 0.96 |
Triglycerides | 12.85 | 0.59, 25.12 | 0.04 |
TC/HDL-C | 0.28 | 0.05, 0.50 | 0.02 |